Does Medicare Cover HRT for Menopause?

Yes — Medicare can cover HRT for menopause. But not the way most people picture it. Your hormone pills, patches, creams, and progesterone are covered through Medicare Part D (the prescription-drug part) or a Medicare Advantage plan that includes drug coverage — notby Original Medicare (Parts A and B) on its own — as long as your exact drug is on your plan’s covered-drug list. Generic estradiol can run as little as $0–$20 a month. The catch comes down to four things: your exact drug, your plan’s list, a few plan rules with scary names, and whether anyone told you the workaround.

By The HRT Index Editorial Team · Last verified June 11, 2026. The HRT Index is an independent comparison resource for HRT telehealth providers. This is coverage education, not medical or insurance advice.

Start here: your situation at a glance

Does Medicare cover HRT for menopause?

“Medicare” isn’t one thing. It’s a few parts, and only one of them is built to pay for the medicine you swallow, stick on, or apply at home. That part is Part D— prescription drug coverage sold by private companies that Medicare approves. If you have a standalone Part D plan, or a Medicare Advantage plan that bundles drug coverage in, you’re in the game. If you only have Original Medicare and never added a drug plan, your estradiol or Premarin isn’t covered — full stop — until you add Part D.

Two big national health outlets — Medical News Today and Healthline — sum it up the same way: Original Medicare generally won’t pay for the hormone medication itself, while Part D or Medicare Advantage drug coverage may, depending on your plan’s details.

The good news for most women: the most common menopause hormones come in cheap, FDA-approved generic versions that plans tend to cover. The frustrating part: “HRT” isn’t one box on a form. A patch, a pill, a vaginal cream, and a compounded cream can all be treated differently — and that’s where people get tripped up.

Which part of Medicare actually pays — Part A, B, C, or D?

• Part A = hospital stays. Not your HRT.
• Part B = doctor visits, outpatient care, and lab tests. It can cover your visit and medically necessary bloodwork — but after your Part B deductible, you usually pay 20% of the approved cost. It is not the path for the patch or pill you take home.
• Part C (Medicare Advantage) = a private all-in-one alternative to Original Medicare. Most of these plans include drug coverage (called MA-PD). KFF reports that 96% of Medicare Advantage enrollees in individual plans for 2026 are in plans that offer drug coverage. If yours includes drugs, that’s your HRT path — with its own network and drug list.
• Part D = standalone prescription drug coverage. This is the most common way menopause HRT gets paid for. Every Part D plan has its own formulary (the list of drugs the plan covers).
• Medigap (Medicare Supplement) = helps pay your share of Part A and B costs. It does not add drug coverage.

What HRT medications does Medicare Part D usually cover? (2026 Coverage Map)

The HRT Index 2026 Medicare Menopause-HRT Coverage Map— Last verified June 11, 2026. Coverage and price vary by plan; cash prices are average retail/list before coupons. Always check your own formulary.

* “With Part D” costs depend on your plan, tier, and pharmacy. They’re realistic ranges, not promises. The 2026 cap means you’ll never pay more than $2,100out of pocket for covered drugs all year. Always confirm your plan’s list.

How much does menopause HRT cost on Medicare in 2026?

Here are the numbers that matter, confirmed for 2026 from Medicare and CMS:

• $615 — the most your Part D deductible can be. Many plans set it lower, or charge $0 for generics. (The deductible is what you pay first, before the plan starts splitting the cost.)
• $2,100 — the out-of-pocket cap. After your deductible, copays, and coinsurance on covered drugs add up to $2,100 in a year, you pay $0 for those covered drugs the rest of the year. This is a hard ceiling. The cap rose to $2,100 for 2026 (it was $2,000 in 2025).
• $5.10 / $12.65 — what covered drugs cost in 2026 if you qualify for Extra Help. Extra Help caps covered generics at $5.10 and covered brand-name drugs at $12.65 for people with limited income and savings, and often wipes out the deductible too.

Two more things worth knowing:

• The donut hole is gone.Medicare simplified Part D into three stages — deductible, then regular coverage, then $0 after the cap. The old “coverage gap” math that used to surprise people is no longer part of it.
• You can spread the cost over the year. The Medicare Prescription Payment Planlets you pay your drug costs in monthly chunks instead of one big hit at the pharmacy. It doesn’t lower your total — it just smooths it out.

The honest catch: who covers the visit vs. who covers the drug

Here’s the honest downside: Original Medicare, by itself, covers noneof your take-home hormone medicine. And the slick online menopause clinics you’ve seen advertised — Midi, Winona, and others — don’t bill Medicare either. Midi says so plainly on its own website: it’s not covered by Medicare or any Medicare-related insurance plan, and it can only see Medicare members as self-pay.

If that’s all you knew, you might assume you’re stuck. You’re not.

Who pays for what, by path — verified June 11, 2026

The single most useful takeaway: if you want menopause-specialized care fast, you can pay for a quick visit andstill let Medicare pay for the medicine — as long as it’s an FDA-approved drug that’s on your plan’s list and sent to your pharmacy.

Heads-up: the provider links in this guide are affiliate links — we may earn a commission if you choose a provider through us, at no extra cost to you. It never changes what we report, and we’ll tell you plainly when your own doctor is the better path.

A note on video visits: under the Consolidated Appropriations Act, 2026, Medicare’s telehealth flexibilities — including getting care from home with no rural requirement — are extended through December 31, 2027. This covers telehealth from a clinician who bills Medicare — the self-pay clinics above aren’t Medicare-enrolled, so their visits stay self-pay.

How do you check whether YOUR plan covers YOUR exact prescription?

Three plan-rule terms, defined once so they stop being scary:

• Prior authorization (PA): the plan wants your doctor to get approval before it will pay.
• Step therapy (ST):the plan wants you to try a cheaper drug first, and only covers the pricier one if that doesn’t work.
• Quantity limit (QL): the plan only covers a set amount in a set time.

Step 1 — Get your exact prescription details.

Pull these off your bottle or ask your pharmacy: drug name (brand or generic), form (patch, pill, cream, capsule, ring), strength (the milligram or dose), quantity and days’ supply, and the NDC number if the pharmacy can give it (this is the exact product code).

Step 2 — Look it up on your plan’s drug list.

Step 3 — Check for the three rules and the tier.

Is it covered? What tier (which sets your copay)? Does it need PA, ST, or a QL? Is there a preferred pharmacyor mail-order option that’s cheaper?

Step 4 — Compare your plan price to the cash price.

Sometimes a cash discount beats your copay. Just remember the trade-off: cash spending usually doesn’t count toward your $2,100 cap.

A script you can read straight to your plan or pharmacist:

“Is [drug name, form, strength] on my 2026 formulary? What tier is it? Does it need prior authorization, step therapy, or have a quantity limit? Is there a cheaper preferred or mail-order option — and which choice counts toward my Part D out-of-pocket cap?”

What if Medicare paid for your HRT last month — but now says it’s not covered?

This is one of the most upsetting moments — you finally found something that helps, and the pharmacy says no. Take a breath. Here’s what’s usually behind it:

• The January reset. Plans update their drug lists every year. A drug covered in December can move tiers, need approval, or drop off on January 1.
• You changed plans (or your plan changed its rules).
• A new prior authorization or step therapy requirement appeared.
• A quantity limit capped your amount.
• Your pharmacy went out of network.
• A patch shortage forced a substitution.This is real right now — more on it below.
• Brand vs. generic mismatch, or your prescriber wrote a slightly different form or strength.

Do these three things, in order:

1. Ask the pharmacy for the rejection reason or code. They can see exactly why it bounced.
2. Call your plan and ask: is this a formulary, PA, step-therapy, quantity, or tier issue?
3. Ask your prescriberwhether a covered alternative is medically right for you — or whether they’ll support an exception.

What to do if your plan denies HRT or demands prior authorization

Here’s the path, step by step:

1. Get the denial reason in writing. Medicare drug plans have several levels of appeal, and each level gives you a decision letter with instructions for the next one. Keep every letter.
2. Ask for a coverage determination or exception. CMS says you, your prescriber, or your representative can ask the plan for a standard or expedited (faster) decision.
3. Get your prescriber’s support.A short supporting statement from your doctor — why this drug, why not the alternative — does a lot of the heavy lifting.

A message you can send your prescriber’s office:

“My Medicare drug plan denied [drug, form, strength]. Could you tell me if a covered alternative is medically appropriate for me — or provide a supporting statement for a prior authorization, exception, or appeal?”

Keep going if the first answer is no. The appeal levels exist precisely because plans don’t always get it right the first time.

Does Medicare cover estradiol patches, pills, gels, or vaginal estrogen?

• Estradiol patches. Generic patches at retail often run $20–$40/monthwith a discount, and many plans cover them at a low tier. But they’ve been hard to find lately— more on the shortage below.
• Estradiol gels and sprays.Also covered when on your plan’s list; cost varies by product. Confirm the exact brand or generic on your formulary.
• Oral estradiol or conjugated estrogens (Premarin).Part D may cover these. Premarin tends to cost more and can sit behind step therapy because there’s no U.S. generic.
• Vaginal estrogen (cream, tablet, ring). FDA-approved for menopause-related vaginal dryness and painful sex. If your only bother is vaginal symptoms, Mayo Clinic notes that low-dose vaginal estrogen is often used instead of whole-body therapy — a conversation to have with your clinician.

A timely heads-up: the 2026 estradiol patch shortage

Ask your pharmacist about other strengths, other pharmacies, or an FDA-approved alternative your prescriber approves. Don’t switch forms on your own.

Does Medicare cover progesterone with estrogen therapy?

Why progesterone comes up so often with menopause HRT: the FDA’s progesterone label supports its use to help prevent overgrowth of the uterine lining (called endometrial hyperplasia) in women past menopause who have a uterus and are taking estrogen. That’s a safety pairing, not an upsell.

Two coverage tips:

• Separate generic progesterone vs. a combo product. A standalone generic progesterone capsule may price very differently from a brand-name combination estrogen-progestin product. Ask which your plan covers better.
• Ask your plan directly: “Is generic progesterone capsule [strength] on my 2026 list? What tier? Any prior authorization, step therapy, or quantity limit?”

Does Medicare cover compounded or “bioidentical” hormones and pellets?

Let’s be precise here, because the marketing around this gets blurry:

• “Compounded” does not mean “FDA-approved.” A compounding pharmacy mixes a custom product. That custom product hasn’t gone through FDA approval, and the FDA doesn’t verify it for safety, effectiveness, or quality before it reaches you.
• Why coverage is so hard. Some compounded products are cash-pay only. Under Medicare Part B billing rules, CMS guidance treats self-administered compounded drugs as not a covered Medicare service.
• Pellets. Treat any claim of Medicare coverage for hormone pellets as unproven. Verify with your plan, in writing, before you pay.

See our full insurance vs. compounded HRT guide for more detail on how FDA-approved and compounded products are treated differently by payers.

What about non-hormonal options — does Medicare cover Veozah?

Veozah (generic name: fezolinetant) became a more popular alternative right as HRT got friendlier labels. The irony worth knowing: six menopausal hormone products just had their boxed warning lifted, while Veozah still carries one — for potential liver injury.

What that liver warning means in practice, straight from the FDA-approved label: your prescriber checks liver blood tests before you start, then monthly for the first 3 months, and again at 6 and 9 months. Veozah is not for women with known cirrhosis, severe kidney problems, or anyone taking certain interacting medicines.

For Medicare members specifically:

• Part D may cover it, often with prior authorization or step therapy, on a high tier.
• The drugmaker’s copay card does NOT work with Medicare— that’s standard for federal programs. Instead, if your plan covers Veozah, your spending counts toward the $2,100 cap, and Extra Help can lower the cost to $12.65 for a brand drug if you qualify.

For more on Veozah’s cost and coverage, see our Veozah cost guide and where to get Veozah online.

Why is it suddenly easier to get HRT prescribed? The 2026 FDA change

For two decades, menopause hormone products carried the FDA’s most serious alert — the “boxed warning” — about risks like stroke, heart attack, breast cancer, and dementia. That warning kept a lot of women, and a lot of doctors, away from a treatment that can help.

Here’s what actually changed, straight from the FDA:

• What was removed: the boxed-warning statements about cardiovascular disease, breast cancer, and probable dementia — on six menopausal hormone therapy products.
• What stayed: the endometrial-cancer warning on whole-body, estrogen-only products.
• Why: the FDA pointed to evidence that the benefits can outweigh the risks for many women who start therapy under age 60 or within about 10 years of menopause.

Coverage rules didn’t change because of this — your plan’s formulary is still the final word. But many prescribers are now more comfortable writing HRT, which is part of why more women are seeking it now and why demand (and the patch shortage) has surged.

Online menopause care and Medicare: who can actually help?

Provider policies verified June 11, 2026; confirm at checkout.

Among these, for a Medicare member who wants specialist care fast, Midi is our pick — it’s FDA-approved-leaning, sees patients in all 50 states, and sends FDA-approved prescriptions to your pharmacy so your Part D plan can cover the drugwhen it’s on your list.

When does paying cash for an online clinic still make sense?

Cash-pay may be worth it if:

• You have Original Medicare with no Part D plan.
• Your plan deniedthe drug and an appeal will take time you don’t have.
• You’re caught in a prior-authorization delay and need relief now.
• Your pharmacy is out of stock(hello, patch shortage) and a clinic can route you to what’s available.
• You value a fast, transparentvisit and accept Medicare won’t reimburse it.

Stick with the Medicare path if:

• You expect high yearly drug costs (you want that $2,100 cap working for you).
• You need your Part D claims tracked toward the cap.
• You qualify for Extra Help.
• You can’t comfortably afford cash prescriptions.

What risks should you talk through before starting or continuing HRT after 65?

• What the FDA says. The FDA’s patient information notes that menopause hormone medicines can raise the chance of blood clots, heart attack, stroke, breast cancer, and dementia in women 65 and older — and that estrogen-only therapy can raise endometrial cancer risk in women with a uterus unless a progestin is used as directed. The newer label changes don’t erase the need for a personal risk talk.
• What Mayo Clinic says. Risks depend on the type, dose, duration, route, and timing, plus your own health history. Therapy should be tailored to you and reviewed over time.
• The Medicare-age wrinkle. Because the strongest benefit evidence is for women who start under 60 or within about 10 years of menopause, many Medicare members are outside that window — which is a reason to discuss it carefully, not a reason to rule it out.

The fastest path if you need HRT covered, not just prescribed

What women on Medicare are actually asking

We read through public menopause forums to understand the real friction — not for medical advice, just to hear how people describe what they’re hitting. The same worries come up again and again: it was covered in December and now it’s suddenly not (usually the January reset or a new rule), why wouldn’t women’s hormones be covered(they often are — through Part D, not Original Medicare), how are other people actually paying for HRT (a mix of Part D, generics, discount cards, and self-pay clinics), and my patch is on backorder everywhere(the real, ongoing shortage — ask about alternatives).

These are themes from public forum discussions, used to understand coverage confusion. They are not medical evidence and not a claim about typical results.

How we built this guide — and what we actually verified

We built this from primary sources: Medicare.gov and CMS for the 2026 rules, the FDA and DailyMed for drug-label facts, and the providers’ own pages for their payment policies. Our recommendations are editorial conclusions based on verified fit — not on which company pays us most.

• Midi’s own policy that it is not covered by Medicare or any Medicare-related plan, and sees Medicare members only as self-pay (joinmidi.com).
• The 2026 Medicare Part D numbers: a $2,100 out-of-pocket cap, a $615 maximum deductible, and Extra Help copays of $5.10 generic / $12.65 brand (CMS / Medicare.gov / NCOA / KFF).
• The FDA’s February 12, 2026 action removing selected boxed-warning statements from six menopausal hormone therapy products (FDA press release and Menopause Society statement).
• Veozah’s boxed warning and liver-monitoring schedule (Astellas/FDA label on DailyMed).
• Current cash and Part D cost ranges for estradiol, Premarin, vaginal estrogen, and Veozah (GoodRx, SingleCare, manufacturer sources).
• Medicare’s telehealth flexibilities extended through December 31, 2027 (Consolidated Appropriations Act, 2026).
• The estradiol patch shortage (American Society of Health-System Pharmacists; AARP; national reporting).

Last verified: June 11, 2026. Next scheduled check: July 2026 (provider policies, pricing, patch supply) and October–November 2026 (2027 Medicare drug-plan numbers).

This page contains affiliate links, which means The HRT Index may earn a commission if you choose a provider through us — at no extra cost to you. It never changes what we report, and we route you to your own doctor and your Part D plan when that’s the better path.

Frequently asked questions

The HRT Index is an independent comparison resource for HRT telehealth providers. We don’t rank providers by who pays us the most — we rank them by who fits the reader. Editorial research only; not medical advice. Talk to your clinician about what’s right for you.